ASND

Ascendis Pharma A/S Form 6-K Summary

Business Context and Reporting Period

This report covers the unaudited condensed consolidated interim financial statements for the three and six months ended June 30, 2026. Ascendis Pharma A/S is a global biopharmaceutical company focused on its TransCon technology platform, primarily commercializing products for endocrinology rare diseases. Key products include YORVIPATH (hypoparathyroidism), SKYTROFA (growth hormone deficiency), and YUVIWEL (achondroplasia).

Key Financial Metrics (Six Months Ended June 30, 2026)

Note: All figures are in thousands of Euros (EUR'000) unless otherwise specified.

Material Changes vs. Prior Period

• Revenue Growth: Revenue increased by 126% (€326.9 million) compared to the six months ended June 30, 2025, driven primarily by the global expansion of YORVIPATH sales and the U.S. launch of YUVIWEL.
• Profitability Turnaround: The company reported a net profit of €836.3 million, a reversal from a net loss of €133.5 million in the prior year. This was significantly influenced by a one-time non-cash income tax benefit of €654.4 million (recognition of deferred tax assets) and €158.1 million in "Other operating income" from the sale of a Rare Pediatric Disease Priority Review Voucher (PRV).
• Debt Reduction: On May 6, 2026, the company completed the optional redemption of all outstanding $575 million 2.25% convertible notes. Holders converted the notes into 3.6 million ordinary shares, eliminating the associated borrowings and derivative liabilities (totaling €719.4 million) and reclassifying them to equity.
• Expense Increases: Selling, general, and administrative (SG&A) expenses rose by €110.0 million year-over-year due to commercial expansion and global launch activities.

Guidance, Outlook, and Significant Events

• Product Launches: YUVIWEL received FDA accelerated approval in February 2026 and began U.S. sales in Q2 2026. A Marketing Authorisation Application (MAA) for YUVIWEL is under review in the EU with a decision expected in Q4 2026.
• Strategic Collaborations: The company continues its collaboration with Novo Nordisk for metabolic diseases (including a once-monthly TransCon Semaglutide candidate) and maintains partnerships with Teijin (Japan) and VISEN (Greater China).
• Share Repurchases: Under a $120 million program authorized in January 2026, the company repurchased approximately 505,000 shares for €103.4 million during the first half of 2026.
• Liquidity: Management estimates existing cash and cash equivalents (€812.3 million) are sufficient to fund operations for at least twelve months from the filing date.
• Risks: The company faces ongoing litigation with BioMarin regarding patent infringement claims related to TransCon CNP, though recent rulings have been favorable to Ascendis (e.g., revocation of the '863 patent by the EPO). Tariff uncertainties in the U.S. remain a monitored risk.

Investor Verification Checklist

• Deferred Tax Assets: Verify the sustainability of the €699.3 million deferred tax asset recognition, which drove the majority of the net profit increase.
• PRV Sale Proceeds: Confirm the one-time nature of the €158.1 million income from the Priority Review Voucher sale and its impact on future earnings expectations.
• Convertible Note Conversion: Review the dilution impact of the 3.6 million shares issued upon the conversion of the $575 million convertible notes.
• YUVIWEL Commercialization: Assess the trajectory of YUVIWEL sales following its Q2 2026 U.S. launch and the timeline for EU approval.
• Royalty Funding Liabilities: Monitor the €301.8 million royalty funding liabilities with Royalty Pharma and their impact on future cash flows based on revenue multiples.